Epidemiological screening and detection indicators for hepatitis D and suitable populations

Xiumei CHI; Junqi NIU

doi:10.3969/j.issn.1001-5256.2023.04.006

Volume 39 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(4): 771-775

PDF( 1899 KB)

Epidemiological screening and detection indicators for hepatitis D and suitable populations

DOI: 10.3969/j.issn.1001-5256.2023.04.006

Xiumei CHI¹,
Junqi NIU^{2
,
,
,}

1.
Gene Therapy Laboratory, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun 130061, China
2.
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun 130021, China

Research funding:

National Natural Science Foundation of China (81970519);

Natural Science Foundation of Jilin Province (YDZJ202201ZTYS016)

More Information

Corresponding author: NIU Junqi, junqiniu@jlu.edu.cn (ORCID: 0000-0001-5415-2024)
Received Date: 2023-02-09
Accepted Date: 2023-03-09
Published Date: 2023-04-20

Abstract

Abstract

Hepatitis D virus (HDV) infection requires the participation of hepatitis B virus (HBV), which accelerates disease progression after infection and induces a high risk of progression to end-stage liver diseases such as liver cirrhosis and liver cancer. With the gradual increase in the understanding of hepatitis D in the whole society, some therapeutic drugs for hepatitis D have become a research hotspot in recent years, and with the further improvement in clinical testing methods, researchers have started to pay attention to the epidemiological investigation of hepatitis D. Although many studies have been conducted for the specific situation of HDV infection in China, large data deviation is observed due to small cohorts with strong regional features. This article briefly reviews the population, methods, and indicators in the current epidemiological investigation of hepatitis D and discusses related key issues, in order to obtain more accurate epidemiological data, effectively screen out HDV infection, and provide help for early clinical intervention and treatment.
- Hepatitis Delta Virus,
- Epidemiology,
- Diagnostic Techniques and Procedures

FullText(HTML)

References(32)

References

[1]	URBAN S, NEUMANN-HAEFELIN C, LAMPERTICO P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease[J]. Gut, 2021, 70(9): 1782-1794. DOI: 10.1136/gutjnl-2020-323888.
[2]	MENTHA N, CLÉMENT S, NEGRO F, et al. A review on hepatitis D: From virology to new therapies[J]. J Adv Res, 2019, 17: 3-15. DOI: 10.1016/j.jare.2019.03.009.
[3]	LEMPP FA, NI Y, URBAN S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(10): 580-589. DOI: 10.1038/nrgastro.2016.126.
[4]	WANG W, LEMPP FA, SCHLUND F, et al. Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates[J]. J Hepatol, 2021, 75(2): 311-323. DOI: 10.1016/j.jhep.2021.03.025.
[5]	STOCKDALE AJ, KREUELS B, HENRION M, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
[6]	ZI J, GAO X, DU J, et al. Multiple regions drive hepatitis delta virus proliferation and are therapeutic targets[J]. Front Microbiol, 2022, 13: 838382. DOI: 10.3389/fmicb.2022.838382.
[7]	GILLICH N, ZHANG Z, BINDER M, et al. Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication[J]. J Hepatol, 2023, 78(1): 78-89. DOI: 10.1016/j.jhep.2022.08.041.
[8]	KOHSAR M, LANDAHL J, NEUMANN-HAEFELIN C, et al. Human hepatitis D virus-specific T cell epitopes[J]. JHEP Rep, 2021, 3(4): 100294. DOI: 10.1016/j.jhepr.2021.100294.
[9]	LUCIFORA J, DELPHIN M. Current knowledge on hepatitis delta virus replication[J]. Antiviral Res, 2020, 179: 104812. DOI: 10.1016/j.antiviral.2020.104812.
[10]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[11]	CHEN LY, PANG XY, GOYAL H, et al. Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis[J]. Gut Pathog, 2021, 13(1): 66. DOI: 10.1186/s13099-021-00462-0.
[12]	LAZARUS JV, AL-RIFAI A, SANAI FM, et al. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review[J]. Liver Int, 2022. DOI: 10.1111/liv.15338.[Online ahead of print]
[13]	VLACHOGIANNAKOS J, PAPATHEODORIDIS GV. New epidemiology of hepatitis delta[J]. Liver Int, 2020, 40 Suppl 1: 48-53. DOI: 10.1111/liv.14357.
[14]	WRANKE A, HEIDRICH B, ERNST S, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta[J]. PLoS One, 2014, 9(7): e101002. DOI: 10.1371/journal.pone.0101002.
[15]	CHEN X, OIDOVSAMBUU O, LIU P, et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians[J]. Hepatology, 2017, 66(6): 1739-1749. DOI: 10.1002/hep.28957.
[16]	LEMPP FA, ROGGENBACH I, NKONGOLO S, et al. A rapid point-of-care test for the serodiagnosis of hepatitis delta virus infection[J]. Viruses, 2021, 13(12): 2371. DOI: 10.3390/v13122371.
[17]	HOBLOS R, KEFALAKES H. Immunology of hepatitis D virus infection: General concepts and present evidence[J]. Liver Int, 2022. DOI: 10.1111/liv.15424.[Online ahead of print]
[18]	DANDRI M, BERTOLETTI A, LVTGEHETMANN M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition[J]. Semin Immunopathol, 2021, 43(4): 535-548. DOI: 10.1007/s00281-021-00864-x.
[19]	YAO T, LV M, MA S, et al. Ubiquitinated hepatitis D antigen-loaded microvesicles induce a potent specific cellular immune response to inhibit HDV replication in vivo[J]. Microbiol Spectr, 2021, 9(3): e0102421. DOI: 10.1128/Spectrum.01024-21.
[20]	XU L, ZHANG X, CAO Y, et al. Digital droplet PCR for detection and quantitation of hepatitis delta virus[J]. Clin Transl Gastroenterol, 2022, 13(7): e00509. DOI: 10.14309/ctg.0000000000000509.
[21]	PFLVGER LS, NÖRZ D, VOLZ T, et al. Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system[J]. JHEP Rep, 2021, 3(6): 100356. DOI: 10.1016/j.jhepr.2021.100356.
[22]	PALOM A, SOPENA S, RIVEIRO-BARCIELA M, et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease[J]. Aliment Pharmacol Ther, 2021, 54(4): 462-469. DOI: 10.1111/apt.16485.
[23]	ZHANG Z, NI Y, LEMPP FA, et al. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread[J]. J Hepatol, 2022, 77(4): 957-966. DOI: 10.1016/j.jhep.2022.05.023.
[24]	ROULOT D, BRICHLER S, LAYESE R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta[J]. J Hepatol, 2020, 73(5): 1046-1062. DOI: 10.1016/j.jhep.2020.06.038.
[25]	SCHWARZ C, CHROMY D, BANGERT C, et al. Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis[J]. J Hepatol, 2022, 77(1): 254-255. DOI: 10.1016/j.jhep.2022.03.004.
[26]	LIN YX, QIN YL, ZHANG JM. Clinical significance and methods of hepatitis D virus RNA detection[J]. J Clin Hepatol, 2022, 38(12): 2830-2835. DOI: 10.3969/j.issn.1001-5256.2022.12.028. 林妍雪, 秦艳丽, 张继明. HDV RNA检测的临床意义与方法[J]. 临床肝胆病杂志, 2022, 38(12): 2830-2835. DOI: 10.3969/j.issn.1001-5256.2022.12.028.
[27]	KATSOULIDOU A, MANESIS E, ROKKA C, et al. Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D[J]. J Viral Hepat, 2013, 20(4): 256-262. DOI: 10.1111/jvh.12000.
[28]	SCHOLTES C, ICARD V, AMIRI M, et al. Standardized one-step real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis delta virus from clinical samples in the presence of a heterologous internal-control RNA[J]. J Clin Microbiol, 2012, 50(6): 2126-2128. DOI: 10.1128/JCM.06829-11.
[29]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[30]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[31]	RIZZETTO M, HAMID S, NEGRO F. The changing context of hepatitis D[J]. J Hepatol, 2021, 74(5): 1200-1211. DOI: 10.1016/j.jhep.2021.01.014.
[32]	BÉGUELIN C, ATKINSON A, BOYD A, et al. Hepatitis delta infection among persons living with HIV in Europe[J]. Liver Int, 2023. DOI: 10.1111/liv.15519.[Online ahead of print]

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (554) PDF downloads(97)

Epidemiological screening and detection indicators for hepatitis D and suitable populations

DOI: 10.3969/j.issn.1001-5256.2023.04.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Epidemiological screening and detection indicators for hepatitis D and suitable populations

DOI: 10.3969/j.issn.1001-5256.2023.04.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content